Alere Syphilis TP

This package insert must be read carefully prior to use. Package insert instructions must be followed accordingly. Reliability of assay results cannot be guaranteed if there are deviations from the instructions in this package inser

### NAME AND INTENDED USE

Mere Determine M Syphilis TP is an In Vitra, visually read, qualitative immunoassay for the detection of antibodies to Treponema pallidum, which is the bacteria that causes syphilis infection, in human serum, plasma or whole blood. The test is intended as an aid to detect antibodies to Treponema pallidum from infected individuals.

### SUMMARY AND EXPLANATION OF THE TEST

SUMMARY AND EXPLANATION OF THE TEST
Syphilis is caused by infection with the bacterium Treponema pallidum¹ which can be transmitted congenitally or by sexual contact. The disease can evolve into a latent phase in which syphilis is clinically inapparent. Serologic tests (nontreponemal specific and treponemal specific) are currently the primary method for syphilis diagnosis and management. Nontreponemal tests (VDRL, RPR, etc.) are generally used for screening, and treponemal tests (TPHA, FTA-ABS, etc.) are used as confirmatory tests.

## BIOLOGICAL PRINCIPLES OF THE PROCEDURE

tographic test for the qualitative detection of antibodies to Trepon Alere Determine<sup>T</sup> pallidum antigens

Sample is added to the sample pad. As the sample migrates through the conjugate pad, it reconstitutes and mixes with the Treponema pallidum antigen-selenium colloid conjugate. This mixture continues to migrate through the solid phase to the immobilized Treponema pallidum antigens at the patient window site.

immobilized Treponema pallidum antigens at the patient window site.

If antibodies to Treponema pallidum are present in the sample, the antibodies bind to the Treponema pallidum antigenselenium colloid and to the Treponema pallidum antigen at the patient window, forming a red line at the patient window site if antibodies to Treponema pallidum are absent, the Treponema pallidum antigen-selenium colloid flows past the patient window site.

To ensure assay validity, a procedural control bar is incorporated in the assay device.

### CONTENTS

Alere Determine™ Syphilis TP, 30 Tests (7D2442) or 100 Tests (7D2443)

Alere Determine™ Syphilis TP Test Card. 3 or 10 cards (10 tests/card). Treponema pallidum antigen coated.

## ACCESSORIES (required but not provided)

CHASE BUFFER
 1 Bottle (2.5 mL) Chase Buffer (7D2243) prepared in phosphate buffer.
 Preservatives: Antimicrobial Agents.

### Whole Blood (fingerstick assay)

- EDTA CAPILLARY TUBES (Mylar-coated) 7D2227
- EDTA Capillary Tubes (Non-Mylar-coated / Not available in CE countries) 7D2222

## WARNINGS AND PRECAUTIONS

For professional use only

# CAUTION

This product contains human sourced infectious and/or potentially infectious components. Refer to the CONTENTS section of this package insert. No known test method can offer complete assurance that products derived from human sources or inactivated mitororoganisms will not transmit infection. Therefore, it is recommended that all human sourced materials be considered potentially infectious and handled with appropriate biosafety practices.<sup>2,3</sup>

## STORAGE

Altere Determine™ Syphilis TP Test and the Chase Buffer must be stored at 2-30°C until expiration date. Kit components are stable until expiration date when handled and stored as directed. Do not use kit components beyond expiration date. Immediately reseal all unused tests in the foil pouch containing the desic.cart by pressing seal from end to end to close. Do not use devices that have become wet or the packaging has become damaged.

## SPECIMEN COLLECTION

Serum, Plasma, and Whole Blood Collection by Venipuncture
Human serum, plasma, and whole blood collected by venipuncture should be collected aseptically in such a way as to avoid hemolysis

Specimens showing particulate matter or turbidity should be centrifuged before testing in order to avoid providing erroresults.

NOTE: For whole blood specimens, EDTA collection tubes must be used.

## Whole Blood Collection by Fingerstick<sup>4</sup>

Before collecting a fingerstick specimen, place an EDTA capillary tube on a clean dry surface

- Choose the fingertip of the middle, ring, or index finger (whichever is the least callused) for adults and children older than one year. Warm the hand as needed with a warm, moist tow warm water to increase blood flow.
- 2. Clean fingertip with alcohol; allow to air dry. Position the hand palm-side up
- 3. Use a new lancet for each person. Place the lancet off-center on the fingertip. Firmly press the lancet against the finger and puncture the skin. Dispose of the lancet in an appropriate biohazard sharps contained
- 4. Wipe away the first drop of blood with a sterile gauze pad.
- Hold the finger lower than the elbow and apply gentle, intermittent pressure to the base of the punctured finger several times. Touch the tip of the EDTA Capillary Tube to the drop of blood\*. Avoid air bubbles.





## SPECIMEN STORAGE

- Serum and plasma specimens should be stored at 2-8°C if the test is to be run within 7 days of collection. If testing is delayed more than 7 days, the specimen should be frozen (-20°C or colder).
- Whole blood collected by venipuncture should be stored at 2-8°C if the test is to be run within 7 days of collection. Do not freeze whole blood specimens.
- Whole blood collected by fingerstick should be tested immediately

August 2013 241021/R6

The desired number of test units from the 10-test card can be removed by bending and tearing at the perforation NOTE:

- val of the test units should start from the right side of the test card to preserve the lot number which appears on the left side of the test card.
- Assay should be initiated within 2 hours after removing the protective foil cover from each test.
- ve the protective foil cover fro
- remove the protective to il cover more acen test.

  For serum or plasma samples:

  a. Apply 50 µL of sample (precision pipette) to the sample pad (marked by the arrow symbol).

  b. Walt a minimum of 15 minutes (up to 24 hours) and read result.

  For whole blood (venipuncture) samples:

  a. Apply 50 µL of sample (precision pipette) to the sample pad (marked by the arrow symbol).

  b. Walt one minute, then apply one drop of Chase Buffer to the sample pad.

  c. Walt a minimum of 15 minutes (up to 24 hours) and read result.

  For whole Blood (fignestrictly samples:

- 4. For whole blood (fingerstick) samples:

  - a. Apply 50 µL of sample (by EDTA capillary tube) to the sample pad (marked by the arrow symbol).

    b. Walt until blood is absorbed into the sample pad, then apply one drop of Chase Buffer to the sample pad.

    c. Walt a minimum of 15 minutes (up to 24 hours) and read result.


## **OUALITY CONTROL**

To ensure assay validity, a procedural control is incorporated in the device and is labeled "Control". If the control bar does not turn red by assay completion, the test result is invalid and the sample should be retested.

### INTERPRETATION OF RESULTS


### POSITIVE (Two Bars)

Red bars appear in both the control window (labeled "Control") and the patient window (labeled "Patient") of the strip. Any visible red bar in the patient window should be interpreted as positive.



### NEGATIVE (One Bar)

One red bar appears in the control window of the strip (labeled "Control"), and no red bar appears in the patient window of the strip (labeled "Patient").



### INVALID (No Bar)

If there is no red bar in the control window of the strip, and even if a red bar appears in the patient window of the strip, the result is invalid and should be repeated

### NOTES:

- The test result is positive even if the patient bar appears lighter or darker than the control bar.
- . If an invalid test result occurs repeatedly, or for technical assistance, contact your local distributor or call Technical Support.

## LIMITATIONS OF THE PROCEDURE

- **Alere** Determine™ Syphilis TP is designed to detect antibodies to *Treponema pallidum* in human serum, plasma, and whole blood. Other body fluids or pooled specimens may not give accurate results.
- The intensity of the patient bar does not necessarily correlate to the titer of antibody in the specimen
- No diagnostic test provides absolute assurance that a sample does not contain either low levels of antibodies to Treponema pallidum, such as those present at a very early stage of infection, or antibodies with low reactivity to the Treponema pallidum antigers. Therefore, a negative result at any time does not preclude the possibility of exposure to infection with syphilis. If the overall clinical evaluation suggests that either of the conditions described above is present, reading the test results after at least 30 minutes up to overnight as allowed in the instructions for use is recommended to maximize test sensitivity.
- Positive specimens should be evaluated in light of the overall clinical evaluation before a diagnosis is m
- . Whole blood or plasma specimens containing anticoagulants other than EDTA may give incorrect results.

# SPECIFICITY AND SENSITIVITY

Serum specimens from 325 cases of non-syphilis and 176 cases of syphilis from three clinical sites in Japan were tested by Alere Determine™ Syphilis TP and two commercially available tests (Table I).

Table I Specificity and Sensitivity of Alere Dete ne™ Syphilis TP for Detection of Syphilis

	Population	Number of Specimens Tested	Alere Determine™ Syphilis TP	Commercially Available Test A	Commercially Available Test B
			100.00%	100.00%	100.00%
Specificity	Non-syphilis	325	(325/325)	(325/325)	(325/325)
			100.00%	97.73%	94.32%
Sensitivity	Syphilis	176	(176/176)	(172/176)	(166/176)

Whole blood specimens with paired serum and plasma from 47 cases of non-syphilis and 52 cases of syphilis from three clinical sites in Japan were tested with **Alere** Determine™ Syphilis TP and two commercially available tests (Table II).

Table II Specificity and Sensitivity of Alere Determine™ Syphilis TP in Whole Blood and Paired Serum and Plasma Specimens

	Population	Number of Specimens Tested Alere Determine™ Syphilis TP			philis TP	Commercially Available Test A	Commercially Available Test B
			Whole Blood	Plasma	Serum	Serum	Serum
Specificity	Non-syphilis	47	100.00% (47/47)	100.00% (47/47)	100.00% (47/47)	100.00% (47/47)	100.00% (47/47)
Sensitivity	Syphilis	52	92.31% (48/52)	100.00% (52/52)	100.00% (52/52)	98.08% (51/52)	94.23% (49/52)

## BIBLIOGRAPHY (See back page)

## Advice Line (See back page)

The manufacturing process produces different lot numbers for the kit and test cards; these lot numbers are traceable.